Missed GME or NVDA? Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
ROIV Stock Forecast 2025-2026
$10.80
Current Price
$7.72B
Market Cap
Buy 9
Hold 1
Sell 0
Wall St Analyst Ratings
Distance to ROIV Price Targets
+103.7%
To High Target of $22.00
+52.8%
To Median Target of $16.50
+11.1%
To Low Target of $12.00
ROIV Price Momentum
+1.5%
1 Week Change
+6.4%
1 Month Change
-3.8%
1 Year Change
-8.7%
Year-to-Date Change
-17.3%
From 52W High of $13.06
+23.7%
From 52W Low of $8.73
📉 MARKET SELLOFF ALERT
10 Quality Stocks Worth Considering Now
Researching Roivant (ROIV) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on ROIV and similar high-potential opportunities.
Latest ROIV Stock Price Targets & Analyst Predictions
Based on our analysis of 12 Wall Street analysts, ROIV has a bullish consensus with a median price target of $16.50 (ranging from $12.00 to $22.00). The overall analyst rating is Strong Buy (9.0/10). Currently trading at $10.80, the median forecast implies a 52.8% upside. This outlook is supported by 9 Buy, 1 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Allison Bratzel at Piper Sandler, projecting a 103.7% upside. Conversely, the most conservative target is provided by Chi Fong at B of A Securities, suggesting a 11.1% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
ROIV Analyst Ratings
9
Buy
1
Hold
0
Sell
ROIV Price Target Range
Low
$12.00
Average
$16.50
High
$22.00
Current: $10.80
Latest ROIV Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for ROIV.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Apr 21, 2025 | HC Wainwright & Co. | Douglas Tsao | Buy | Reiterates | $18.00 |
| Feb 11, 2025 | HC Wainwright & Co. | Douglas Tsao | Buy | Reiterates | $18.00 |
| Nov 13, 2024 | HC Wainwright & Co. | Douglas Tsao | Buy | Reiterates | $18.00 |
| Sep 19, 2024 | Cantor Fitzgerald | Louise Chen | Overweight | Reiterates | $0.00 |
| Sep 19, 2024 | HC Wainwright & Co. | Douglas Tsao | Buy | Reiterates | $18.00 |
| Sep 11, 2024 | B of A Securities | Chi Fong | Neutral | Maintains | $12.50 |
| Sep 11, 2024 | HC Wainwright & Co. | Douglas Tsao | Buy | Reiterates | $18.00 |
| Sep 9, 2024 | Cantor Fitzgerald | Louise Chen | Overweight | Reiterates | $0.00 |
| Aug 19, 2024 | HC Wainwright & Co. | Douglas Tsao | Buy | Reiterates | $18.00 |
| Jul 10, 2024 | Piper Sandler | Allison Bratzel | Overweight | Maintains | $22.00 |
| Jun 18, 2024 | Cantor Fitzgerald | Louise Chen | Overweight | Reiterates | $0.00 |
| May 31, 2024 | HC Wainwright & Co. | Douglas Tsao | Buy | Reiterates | $18.00 |
| Apr 22, 2024 | HC Wainwright & Co. | Douglas Tsao | Buy | Reiterates | $18.00 |
| Apr 3, 2024 | HC Wainwright & Co. | Douglas Tsao | Buy | Maintains | $18.00 |
| Apr 3, 2024 | Deutsche Bank | Neena Bitritto-Garg | Buy | Maintains | $15.00 |
| Apr 3, 2024 | Goldman Sachs | Corinne Jenkins | Buy | Maintains | $18.00 |
| Mar 25, 2024 | Truist Securities | Robyn Karnauskas | Buy | Reiterates | $23.00 |
| Feb 15, 2024 | Wolfe Research | Andy Chen | Outperform | Initiates | $17.00 |
| Feb 14, 2024 | HC Wainwright & Co. | Douglas Tsao | Buy | Maintains | $17.00 |
| Jan 5, 2024 | Piper Sandler | Allison Bratzel | Overweight | Initiates | $20.00 |
Roivant Sciences Ltd (ROIV) Competitors
The following stocks are similar to Roivant based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Roivant Sciences Ltd (ROIV) Financial Data
Roivant Sciences Ltd has a market capitalization of $7.72B with a P/E ratio of 1.9x. The company generates $122.59M in trailing twelve-month revenue with a -95.1% profit margin.
Revenue growth is -42.1% quarter-over-quarter, while maintaining an operating margin of -2,921.7% and return on equity of -14.6%.
Valuation Metrics
Market Cap
$7.72B
Enterprise Value
$2.98B
P/E Ratio
1.9x
PEG Ratio
-9.1x
Price/Sales
63.0x
Growth & Margins
Revenue Growth (YoY)
-42.1%
Gross Margin
+97.1%
Operating Margin
-2,921.7%
Net Margin
-95.1%
EPS Growth
-96.7%
Financial Health
Cash/Price Ratio
+66.8%
Current Ratio
37.9x
Debt/Equity
1.8x
ROE
-14.6%
ROA
-11.6%
💰 DON'T MISS THIS OPPORTUNITY
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Roivant Sciences Ltd (ROIV) Business Model
About Roivant Sciences Ltd
What They Do
Develops innovative therapies in biopharmaceuticals.
Business Model
Roivant Sciences operates as a platform company that incubates subsidiaries, or 'Vants,' each focused on specific therapeutic areas like neurology, oncology, and immunology. This semi-autonomous model allows for rapid drug development and commercialization, enabling Roivant to efficiently address critical unmet medical needs and generate revenue through successful therapy launches.
Additional Information
Founded in 2014 and headquartered in New York City, Roivant Sciences utilizes technology and data analytics to enhance drug discovery and optimize clinical trials. The company aims to transform traditional drug development paradigms, potentially improving patient outcomes and impacting global healthcare.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
908
CEO
Mr. Matthew Gline
Country
United Kingdom
IPO Year
2020
Website
roivant.comRoivant Sciences Ltd (ROIV) Latest News & Analysis
Featured Analysis
Powered by
Zacks Investment Research
Gossamer Bio (GOSS) Reports Q1 Loss, Tops Revenue Estimates
Gossamer Bio (GOSS) delivered earnings and revenue surprises of 11.11% and 167.27%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
May 15, 2025
By Zacks Equity Research
Tale of the Tape
Codexis (CDXS) Reports Q1 Loss, Misses Revenue Estimates
Codexis (CDXS) delivered earnings and revenue surprises of -25% and 28.99%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
May 14, 2025
By Zacks Equity Research
Tale of the Tape
Spero Therapeutics, Inc. (SPRO) Reports Q1 Loss, Misses Revenue Estimates
Spero Therapeutics (SPRO) delivered earnings and revenue surprises of 54.55% and 46.60%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
May 13, 2025
By Zacks Equity Research
Tale of the Tape
Latest News
Quick Summary
Roivant (Nasdaq: ROIV) will hold a conference call and webcast on May 29, 2025, at 8:00 a.m. ET to discuss Q4 and fiscal year 2025 financial results and business updates.
Why It Matters
Roivant's upcoming financial results call could reveal key insights into its performance and strategic direction, impacting stock valuation and investor sentiment.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Roivant Sciences has $5.2 billion in cash and assets after strategic divestitures, funding its late-stage pipeline, including promising autoimmune treatments IMVT-1402 and brepocitinib in Phase 3 trials.
Why It Matters
Roivant Sciences' strong cash position and promising drug pipeline enhance its growth potential, making it an attractive option for investors focused on biotech advancements and strategic asset management.
Source: Seeking Alpha
Market Sentiment:
Positive
Quick Summary
Eric Venker, M.D. has been appointed CEO of Immunovant, with Tiago Girao as CFO. Venker is currently President and COO of Roivant.
Why It Matters
Leadership changes at Immunovant may impact company strategy and performance, influencing investor confidence and stock valuation. New executives could drive innovation or restructuring.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Roivant Sciences is restructuring its subsidiary Immunovant, with new C-suite appointments and a focus on new disease targets announced on Monday.
Why It Matters
C-suite changes and new disease targets at Immunovant could signal a strategic shift, potentially impacting future performance and investor confidence in Roivant Sciences.
Source: Investors Business Daily
Market Sentiment:
Negative
Quick Summary
Immunovant, Inc. (Nasdaq: IMVT) announced topline results from its Phase 3 study of batoclimab for MG and initial results from its Phase 2b study in CIDP on March 19, 2025.
Why It Matters
Positive Phase 3 results for batoclimab could boost Immunovant's market position and attract investor interest, potentially impacting stock performance and future funding opportunities.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Immunovant, Inc. (Nasdaq: IMVT) will host an investor webcast on March 19, 2025, at 8:00 a.m. ET to discuss Phase 3 study results of batoclimab in MG and Phase 2b results in CIDP.
Why It Matters
The announcement of an investor webcast to discuss Phase 3 and Phase 2b study results indicates potential advancements in Immunovant's drug pipeline, impacting stock performance and investor sentiment.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About ROIV Stock
What is Roivant Sciences Ltd's (ROIV) stock forecast for 2025?
Based on our analysis of 12 Wall Street analysts, Roivant Sciences Ltd (ROIV) has a median price target of $16.50. The highest price target is $22.00 and the lowest is $12.00.
Is ROIV stock a good investment in 2025?
According to current analyst ratings, ROIV has 9 Buy ratings, 1 Hold ratings, and 0 Sell ratings. The stock is currently trading at $10.80. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for ROIV stock?
Wall Street analysts predict ROIV stock could reach $16.50 in the next 12 months. This represents a 52.8% increase from the current price of $10.80. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Roivant Sciences Ltd's business model?
Roivant Sciences operates as a platform company that incubates subsidiaries, or 'Vants,' each focused on specific therapeutic areas like neurology, oncology, and immunology. This semi-autonomous model allows for rapid drug development and commercialization, enabling Roivant to efficiently address critical unmet medical needs and generate revenue through successful therapy launches.
What is the highest forecasted price for ROIV Roivant Sciences Ltd?
The highest price target for ROIV is $22.00 from Allison Bratzel at Piper Sandler, which represents a 103.7% increase from the current price of $10.80.
What is the lowest forecasted price for ROIV Roivant Sciences Ltd?
The lowest price target for ROIV is $12.00 from Chi Fong at B of A Securities, which represents a 11.1% increase from the current price of $10.80.
What is the overall ROIV consensus from analysts for Roivant Sciences Ltd?
The overall analyst consensus for ROIV is bullish. Out of 12 Wall Street analysts, 9 rate it as Buy, 1 as Hold, and 0 as Sell, with a median price target of $16.50.
How accurate are ROIV stock price projections?
Stock price projections, including those for Roivant Sciences Ltd, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: May 18, 2025 10:12 AM UTC